The co-administration of osimertinib (an EGFR inhibitor) and T-DM1 facilitates the enhancement of antitumor effects, and T-DM1 can overcome osimertinib resistance in an EGFR-mutated non-small-cell lung cancer model (101). This evidence concerns the gene EGFR and non-small cell lung carcinoma.